Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments
Ulcerative colitis (UC) is one of the two forms of inflammatory bowel disease. It affects 5
million people globally, and is a chronic and recurring inflammation of the gastrointestinal …
million people globally, and is a chronic and recurring inflammation of the gastrointestinal …
[HTML][HTML] Selective JAK1 inhibitors for the treatment of inflammatory bowel disease
Janus kinase (JAK) inhibitors, also known as jakinibs, are third-generation oral small
molecules that have expanded the therapeutic options for the management of chronic …
molecules that have expanded the therapeutic options for the management of chronic …
Risankizumab for ulcerative colitis: two randomized clinical trials
Importance The clinical effects of risankizumab (a monoclonal antibody that selectively
targets the p19 subunit of IL-23) for the treatment of ulcerative colitis are unknown. Objective …
targets the p19 subunit of IL-23) for the treatment of ulcerative colitis are unknown. Objective …
The future of clinical trials in inflammatory bowel disease
The medical management of inflammatory bowel disease (IBD) has been transformed over
the past few decades by both the approval of multiple classes of advanced therapies as well …
the past few decades by both the approval of multiple classes of advanced therapies as well …
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
YR Bai, DJ Seng, Y Xu, YD Zhang, WJ Zhou… - European Journal of …, 2024 - Elsevier
In 2023, the US Food and Drug Administration has approved 55 novel medications,
consisting of 17 biologics license applications and 38 new molecular entities. Although the …
consisting of 17 biologics license applications and 38 new molecular entities. Although the …
Novel small molecules in IBD: current state and future perspectives
A Jefremow, MF Neurath - Cells, 2023 - mdpi.com
Biologicals have dominated the therapeutic scenery in inflammatory bowel diseases (IBDs),
namely ulcerative colitis (UC) and Crohn's disease (CD), for the past 20 years. The …
namely ulcerative colitis (UC) and Crohn's disease (CD), for the past 20 years. The …
Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta …
Background Randomised placebo-controlled trials for the induction of inflammatory bowel
disease (IBD) remission involve potential harms to those receiving placebo. Whether these …
disease (IBD) remission involve potential harms to those receiving placebo. Whether these …
Current treatments, emerging therapeutics, and natural remedies for inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic, lifelong disorder characterized by
inflammation of the gastrointestinal (GI) tract. The exact etiology of IBD remains incompletely …
inflammation of the gastrointestinal (GI) tract. The exact etiology of IBD remains incompletely …
Sphingosine 1-phosphate signaling during infection and immunity
S Mohammed, A Bindu, A Viswanathan… - Progress in Lipid …, 2023 - Elsevier
Sphingolipids are essential components of all eukaryotic membranes. The bioactive
sphingolipid molecule, Sphingosine 1-Phosphate (S1P), regulates various important …
sphingolipid molecule, Sphingosine 1-Phosphate (S1P), regulates various important …
Emerging therapies for ulcerative colitis: updates from recent clinical trials
T AlAmeel, A AlMutairdi… - Clinical and Experimental …, 2023 - Taylor & Francis
Ulcerative colitis (UC) is a chronic and progressive inflammatory disorder that affects the
colon. The advent of advanced therapies such as biologic agents and small molecules has …
colon. The advent of advanced therapies such as biologic agents and small molecules has …